Efgartigimod
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Key Facts
About Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileAbout Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileAbout Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileAbout Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profile